Supernus Pharmaceuticals, Inc. announces the signing of a definitive licensing agreement with United Therapeutics Corporation for the development of UT-15C, United Therapeutics' oral prostacyclin analog. The licensing agreement contemplates United Therapeutics' development of UT-15C for additional indications. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=2505736)